Texas Permanent School Fund lessened its holdings in Celgene Co. (NASDAQ:CELG) by 0.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 214,931 shares of the biopharmaceutical company’s stock after selling 1,882 shares during the period. Texas Permanent School Fund’s holdings in Celgene were worth $22,430,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in the stock. Thompson Davis & CO. Inc. boosted its holdings in Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares during the last quarter. Arcadia Investment Management Corp MI boosted its holdings in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the last quarter. Robecosam AG acquired a new position in shares of Celgene during the 3rd quarter worth approximately $114,000. Guidant Wealth Advisors acquired a new position in shares of Celgene during the 3rd quarter worth approximately $119,000. Finally, Capital Bank & Trust Co boosted its holdings in shares of Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 517 shares during the last quarter. Hedge funds and other institutional investors own 77.84% of the company’s stock.
In related news, insider Mark J. Alles acquired 3,260 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were acquired at an average price of $91.90 per share, with a total value of $299,594.00. Following the completion of the transaction, the insider now owns 178,904 shares of the company’s stock, valued at $16,441,277.60. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $95.99, for a total value of $887,907.50. Following the sale, the director now directly owns 94,801 shares in the company, valued at approximately $9,099,947.99. The disclosure for this sale can be found here. 0.95% of the stock is currently owned by corporate insiders.
Shares of Celgene Co. (CELG) opened at $93.89 on Thursday. The stock has a market capitalization of $70,591.68, a P/E ratio of 26.23, a price-to-earnings-growth ratio of 0.66 and a beta of 1.49. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 4.80. Celgene Co. has a 12-month low of $88.32 and a 12-month high of $147.17.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.78 by $0.09. The company had revenue of $3.48 billion for the quarter, compared to analyst estimates of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm’s quarterly revenue was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.61 earnings per share. equities research analysts expect that Celgene Co. will post 7.68 EPS for the current year.
Celgene announced that its board has authorized a share repurchase program on Wednesday, February 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.
Several research analysts have recently weighed in on the company. Cann restated a “buy” rating and set a $163.00 target price on shares of Celgene in a report on Thursday, February 15th. BTIG Research restated a “hold” rating on shares of Celgene in a report on Tuesday, January 23rd. Leerink Swann restated a “buy” rating and set a $120.00 target price on shares of Celgene in a report on Friday, December 22nd. Credit Suisse Group set a $125.00 target price on Celgene and gave the stock a “buy” rating in a report on Monday, January 8th. Finally, SunTrust Banks set a $127.00 target price on Celgene and gave the stock a “buy” rating in a report on Monday, January 8th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $130.25.
TRADEMARK VIOLATION WARNING: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/22/celgene-co-celg-position-decreased-by-texas-permanent-school-fund.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.